Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in a Phase I clinical study for its STP705, targeting adult abdominal fat reduction. The study, expected to report results during the first half of 2023, marks a significant step forward in the development of non-invasive fat reduction treatments.
Study Design and Objectives
The dose-setting, randomized, double-blind Phase I study will assess the safety and tolerability of STP705 in patients via subcutaneous injection. Primary endpoints include injection comfort, local and systemic safety, and histological changes resulting from STP705 subcutaneous injection. This comprehensive evaluation aims to determine the optimal dosing regimen for effective abdominal fat reduction.
STP705 Profile
STP705 is a siRNA (small interfering RNA) therapeutic that leverages a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX2 gene expression. The product candidate has received multiple Investigational New Drug (IND) approvals from both the US FDA and China’s National Medical Products Administration (NMPA), including for treatments of cholangiocarcinoma, non-melanoma skin cancer, and hypertrophic scarring.
Non-Invasive Fat Reduction
Non-invasive fat reduction is a therapeutic program aimed at reducing and removing fat accumulation in specific body parts through methods such as cryolysis, radiofrequency, and laser fat decomposition. Traditionally, these methods have provided only mild effects and required multiple treatments. STP705 is expected to offer a new, more effective choice for abdominal fat reduction and subcutaneous tissue remodeling, potentially revolutionizing the field of non-invasive fat reduction.-Fineline Info & Tech
